Associate Professor David Preiss
David Preiss
PhD FRCPath MRCP
Associate Professor
- Honorary Consultant in Metabolic Medicine
MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit
David Preiss studied medicine at the University of Pretoria, South Africa and, after junior doctor training posts in medicine and biochemistry in Scotland, qualified as a consultant in Chemical Pathology and Metabolic Medicine in Glasgow in 2012. He completed his thesis, examining the links between glycaemia and cardiovascular disease, in 2011/2012 and was awarded the University of Glasgow’s Bellahouston Medal for this research. He was recipient of a Rising Star Fellowship from the European Foundation for the Study of Diabetes in 2013, and was also awarded the Royal College of Pathology’s Research Medal for Clinical Biochemistry in 2010. David was appointed as a Senior Clinical Research Fellow at CTSU in September 2015 and as Associate Professor in 2018. He is a previous BHF Centre for Research Excellence Senior Transition Fellow and leads the module on Clinical Trial Reporting and Meta-analyses in the University's MSc on Clinical Trials.
His major interest is the prevention of cardiovascular and microvascular disease with particular focus on lipid modification and diabetes. His current research combines clinical trials, epidemiological studies and meta-analyses of major studies. Current projects include:
- ASCEND PLUS: a randomised trial investigating the effect of the GLP1 receptor agonist, oral semaglutide, on major cardiovascular events in 20,000 participants with type 2 diabetes.
- LENS: a randomised trial investigating the effect of the cholesterol and triglyceride-lowering drug, fenofibrate, on the progression of diabetic eye disease in 1,150 participants with diabetes and observable retinopathy or maculopathy.
- ORION-4: a randomised trial investigating the effect of the LDL cholesterol-lowering drug, inclisiran, on major cardiovascular events in 15,000 participants with cardiovascular disease.
- EMPA-KIDNEY: a randomised trial investigating the effect of the SGLT2 inhibitor, empagliflozin, on worsening of kidney disease or cardiovascular death in 6,600 participants with chronic kidney disease.
- Cholesterol Treatment Trialists' Collaboration: analyses of adverse event data from randomised controlled trials of statin therapy.
Recent publications
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
-
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
-
Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017.
Journal article
Thalmann I. et al, (2022), Heart
-
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
-
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
Journal article
BAIGENT C. et al, (2022), The Lancet
-
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials
-
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329
-
Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
Journal article
Kohli-Lynch CN. et al, (2022), Circulation
-
Impact of ACLY on type 2 diabetes in UK Biobank: a Mendelian randomisation study
Conference paper
Stiby A. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3011 - 3011
-
The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials
Journal article
PREISS D. et al, (2021), Diabetes Care